Economics Highlights: Key reimbursement updates | Medical societies unite for change | AI specialists raise $80M

A cardiologist-led think tank tracked data from more than 1 million procedures, exploring the clinical and economic impacts of implanting low-value coronary stents. 

Intravascular lithotripsy therapy to break up calcified coronary lesions will now be reimbursed at a higher rate under new in-hospital codes the went into effect Oct. 1.

More than 100 U.S. medical societies are throwing their support behind a new proposal that could reform out-of-date Medicare policies and help limit future payment cuts. 

Implanting the Barostim device is now associated with an average payment amount of $45,000, up significantly from the previous average of $29,000.

Ultromics thinks the significant payment increase will help ramp up utilization among U.S. healthcare providers.

The big funding round continues a busy year for Elucid as the company works to get its AI software in the hands of more physicians. 

The drug, nimodipine, is a second-generation calcium channel blocker designed to prevent and treat cerebral vasospasm following an aneurysmal subarachnoid hemorrhage.

DDI currently has contracts with nursing homes and hospitals in 42 states.